Business Wire

Svante and SAMSUNG E&A Sign Joint Development Agreement to Offer Digitally Enabled Skid-Mounted Modular Carbon Capture Plants

Share

Svante and SAMSUNG E&A have signed a joint development agreement to offer standardized skid-mounted modular carbon capture plants based on Svante’s novel VeloxoTherm™ solid sorbent-based carbon capture filter technology, leveraging SAMSUNG E&A’s advanced digital solutions and modularization capabilities. Standardized modular packages will be branded and marketed globally by Svante and SAMSUNG E&A to deliver commercial carbon capture, use, and storage projects from the early project development stage through to engineering, procurement, and fabrication (EPF) across the heavy industrial and energy sectors.

Svante Technologies Inc. (Svante) and SAMSUNG E&A announced today that they have signed a joint development agreement to jointly develop a set of standardized skid-mounted modular carbon capture plants based on Svante’s novel VeloxoTherm solid sorbent-based carbon capture filter technology, leveraging SAMSUNG E&A’s advanced digital solutions and modularization capabilities. The agreement was signed during Svante’s Grand Opening Event, which marked the commissioning of its new commercial filter manufacturing facility in Vancouver, Canada. This is the world’s first gigafactory for Svante’s filter technology, capable of producing enough filters to capture 10 million tonnes of CO2 annually.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513282760/en/

Leaders of SAMSUNG E&A and Svante sign a joint development agreement at a private signing ceremony during Svante's Grand Opening Event in Burnaby, BC, Canada. The companies have partnered to jointly develop and deliver modular, standardized carbon capture plants to industrial facilities worldwide. From the left: Matt Stevenson, CRO, Svante Group, Mark Claessen, President, Svante Solutions & Digital Services, Claude Letourneau, President & CEO, Svante Group, Hong Namkoong, CEO & President, SAMSUNG E&A, Sean Chung, Head of Sustainable Solutions Division, SAMSUNG E&A, Wonsik Cho, VP of Sustainable Solutions, SAMSUNG E&A.

“We are working to remove the biggest barriers to rapid deployment of industrial carbon capture by first building our world-class manufacturing facility and second by partnering with SAMSUNG E&A to reduce project execution schedule and on-site construction costs through standardized design and fabrication solutions,” said Claude Letourneau, President & CEO of Svante.

SAMSUNG E&A, a total solutions provider for the global energy industry, is one of the world’s leading engineering, procurement, and construction (EPC) and project management companies in the world, with an ambition to assist in the energy transition. SAMSUNG E&A’s extensive experience in executing large capital projects based on modularization and digitalization, paired with Svante’s second-generation carbon capture and removal technology, makes this collaboration an innovative, accessible solution for clients in heavy industries and the energy sector looking for engineering-based carbon management solutions.

SAMSUNG E&A is expanding its eco-friendly business portfolio with “E&Able”, a solution that fosters a sustainable future through advanced technology. E&Able embodies SAMSUNG E&A’s commitment to resolving pressing societal challenges such as climate change, by swiftly securing groundbreaking technologies for its customers. It also represents the company’s mission to achieve global objectives, including carbon neutrality and the circular economy, faster. The company is accelerating the promotion of new businesses in the energy transition and eco-friendly sectors, focusing on three E&Able strategies: E&Able Low (low carbon), E&Able Zero (carbon-free), and E&Able Circle (environment). “The time is now for the CCUS industry value chain players to rethink how they approach projects to deliver them faster, more cost-effectively, and more efficiently. Undertaking multiple projects in parallel while using the same EPF contractor will greatly improve project performance,” said Hong Namkoong, President and CEO of SAMSUNG E&A. “Additionally, we have pioneered with our Engineering Data Platform (EDP) utilizing digital tools to enhance project execution efficiency, ultimately driving down schedule timelines and costs.”

Svante has developed a unique, environmentally responsible carbon capture and removal technology, which employs what it calls “structured adsorbent beds”, known as “filters”. The company’s filters are coated with nanoengineered solid adsorbent materials, which can capture CO2 from industrial emissions, including pulp and paper, waste-to-energy, cement, steel, fertilizer, hydrogen, and more. The company’s filter technology can also be leveraged for direct air capture (DAC), in which CO2 that has already been emitted into the atmosphere is trapped and removed from the ambient air.

“We are looking forward to partnering with SAMSUNG E&A to deliver global commercial carbon capture projects at scale,” said Claude Letourneau, Svante’s President and CEO. “SAMSUNG E&A’s 50+ years of experience in modularization across the industrial and energy sectors will be invaluable as we continue to hyperscale our operations and filter manufacturing capacity to expand our order book.”

One of the objectives of this collaboration is to offer industrial customers a one-stop shop via an integrated project delivery model for carbon capture plants. SAMSUNG E&A and Svante will develop standardized advanced front-end (FEL3) engineering package deliverables. During the project execution phase, it is anticipated that SAMSUNG E&A will be the exclusive EPF supplier of skid-mounted modules for CO2 capture plants, while Svante will supply its patented carbon capture machines (contactors)and filter beds. This collaborative approach to building large industrial facilities is shown to be effective at optimizing industrial project management and performance.

“This agreement will assist us in continuing to deliver world-class, environmentally responsible carbon capture plants that provide customers with both cost and schedule certainty, as well as convenient pre-engineered modules and automated data-driven engineering packages -- an offering we can now provide to our clients in addition to the other unique benefits our technology brings.” Letourneau adds, “An integrated project delivery model means customers no longer have to rely on the traditional bid-buy transactional relationships that they’ve been forced to deal with in the past.”

The two companies will work together to identify, develop, and deliver commercial-scale carbon capture projects globally, ensuring heavy industries and energy producers in these regions have more viable pathways to meet their emission reduction targets.

About Svante:

Headquartered in Vancouver, BC, Canada, Svante is a purpose-driven, leading carbon capture and removal solutions provider. The company makes nanoengineered filters and modular rotary contactor machines that capture and remove CO2 in an environmentally responsible way from industrial emissions and the air. Svante is on the 2023 Global Cleantech 100, the XPRIZE Foundation’s XB100 -- World’s Top 100 Deep Tech Companies, and was ranked second among private companies in the Corporate Knights’ Future 50 Fastest Growing Sustainable Companies in Canada. To learn more about Svante, visit www.svanteinc.com and follow Svante on LinkedIn or Twitter @svantesolutions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250513282760/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 04:12:00 CEST | Press release

Results at a glance:71.4% of MetaXplore™ reports from 4,616 patients identified actionable results41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often g

Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 04:00:00 CEST | Press release

Optimizing Global Websites for the Japanese Visitors: Detailed UX/UI Adaptation, Comprehensive Japanese Localization, Extensive Localization and Cultural Relevance to Fit the Local Audience. Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese

Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 03:11:00 CEST | Press release

Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets2 Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 114.5.2025 23:03:00 CEST | Press release

–Data Demonstrated Statistically Significant Improvements in Primary and Secondary Endpoints with Most Subjects Achieving Near Normal Ranges of Wakefulness and Clinically Meaningful Improvements Across the Broad Range of Symptoms Investigated–Oveporexton Found to be Generally Safe and Well Tolerated–Phase 3 Readout of Oveporexton Anticipated in 2025 Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo thro

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 22:05:00 CEST | Press release

Data across 31 abstracts illustrate BeiGene’s deep commitment to transforming treatment for B-cell malignanciesFour oral presentations highlight updated data from investigational BTK protein degrader BGB-16673 and BCL2 inhibitor sonrotoclax across a range of B-cell malignancies BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation scie

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye